{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:26:30Z","timestamp":1793917590955,"version":"4.8.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","award":["IIS-564"],"award-info":[{"award-number":["IIS-564"]}],"id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Functional substrate mapping can identify ventricular tachycardia (VT) ablation targets. Multi-wavefront functional mapping can be laborious. In this study, we explored the feasibility, safety and utility of the new \u201cparallel mapping\u201d algorithm designed to streamline multi-wavefront activation mapping for VT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single center, prospective pilot study of adults undergoing scar-related VT ablation. Patients underwent endocardial and\/or epicardial substrate parallel mapping using 2 distinct activation wavefronts (e.g. right ventricular [RV] and left ventricular [LV] pacing, 8 beats each). Slow-conducting regions were targeted for radiofrequency ablation. Short- and long-term outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 41 ablation subjects, 19 (46.3%) underwent per-protocol parallel mapping. Protocol deviations mostly stemmed from incessant VT necessitating early ablation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099, 40.9%). Most per-protocol treated subjects were male (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918, 94.7%) with a mean age of 66\u2009\u00b1\u200910 years and had a higher prevalence of ischemic heart disease compared to protocol deviations (94.7% vs. 54.6%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Primary wavefront mapping was done during RV apical pacing. Secondary wavefront mapping chiefly relied on LV pacing (52.6%). The median procedure duration was 252\u00a0min (IQR 190\u2013289). Adverse events occurred in 4 patients (21.1%; at most 1 event directly related to study protocol). In the first year of follow-up, seven (36.8%) individuals received appropriate ICD shocks and three (15.8%) patients died. In exploratory analyses, parallel mapping data appeared most informative in subjects with lateral wall scar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Parallel substrate mapping using multiple activation wavefronts is a novel, feasible and safe algorithm designed to identify ablation targets in patients with scar-related VT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-026-02347-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:04:42Z","timestamp":1778043882000},"page":"2399-2409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARALLEL-VT: A pilot study of simultaneous multi-wavefront left ventricular mapping for identification of critical ablation sites"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-5106","authenticated-orcid":false,"given":"Jakub","family":"Sroubek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama M.","family":"Wazni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Anter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"1","key":"2347_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0735-1097(02)02623-2","volume":"41","author":"A Arenal","year":"2003","unstructured":"Arenal A, Glez-Torrecilla E, Ortiz M, Villacastin J, Fdez-Portales J, Sousa E, et al. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol. 2003;41(1):81\u201392. https:\/\/doi.org\/10.1016\/s0735-1097(02)02623-2.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2347_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2015.10.026","volume":"66","author":"L Di Biase","year":"2015","unstructured":"Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P, et al. Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial. J Am Coll Cardiol. 2015;66(25):2872\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.026.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2347_CR3","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/CIRCULATIONAHA.111.043216","volume":"125","author":"P Ja\u00efs","year":"2012","unstructured":"Ja\u00efs P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of local abnormal ventricular activities: A new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125(18):2184\u201396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.043216.","journal-title":"Circulation"},{"issue":"3","key":"2347_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jacep.2017.12.005","volume":"4","author":"A Porta-S\u00e1nchez","year":"2018","unstructured":"Porta-S\u00e1nchez A, Jackson N, Lukac P, Kristiansen SB, Nielsen JM, Gizurarson S, et al. Multicenter Study of Ischemic Ventricular Tachycardia Ablation With Decrement-Evoked Potential (DEEP) Mapping With Extra Stimulus. JACC: Clin Electrophysiol. 2018;4(3):307\u201315. https:\/\/doi.org\/10.1016\/j.jacep.2017.12.005.","journal-title":"JACC: Clin Electrophysiol"},{"issue":"17","key":"2347_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.119.042423","volume":"140","author":"Z Aziz","year":"2019","unstructured":"Aziz Z, Shatz D, Raiman M, Upadhyay GA, Beaser AD, Besser SA, et al. Targeted Ablation of Ventricular Tachycardia Guided by Wavefront Discontinuities during Sinus Rhythm: A New Functional Substrate Mapping Strategy. Circulation. 2019;140(17):1383\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042423.","journal-title":"Circulation"},{"key":"2347_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/circep.120.008625","author":"E Anter","year":"2020","unstructured":"Anter E, Neuzil P, Reddy VY, Petru J, Park K-M, Sroubek J, et al. Ablation of Reentry-Vulnerable-Zones Determined by Left Ventricular Activation from Multiple Directions: A Novel Approach for Ventricular Tachycardia Ablation: A Multicenter Study (PHYSIO-VT). Circulation: Arrhythmia Electrophysiol. 2020. https:\/\/doi.org\/10.1161\/circep.120.008625.","journal-title":"Circulation: Arrhythmia Electrophysiol"},{"issue":"4","key":"2347_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacep.2021.12.013","volume":"8","author":"J Hawson","year":"2022","unstructured":"Hawson J, Anderson RD, Al-kaisey A, Chieng D, Segan L, Watts T, et al. Functional Assessment of Ventricular Tachycardia Circuits and Their Underlying Substrate Using Automated Conduction Velocity Mapping. JACC: Clin Electrophysiol. 2022;8(4):480\u201394. https:\/\/doi.org\/10.1016\/j.jacep.2021.12.013.","journal-title":"JACC: Clin Electrophysiol"},{"issue":"5","key":"2347_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jacep.2015.09.001","volume":"1","author":"ME Josephson","year":"2015","unstructured":"Josephson ME, Anter E. Substrate Mapping for Ventricular Tachycardia Assumptions and Misconceptions. JACC: Clin Electrophysiol. 2015;1(5):341\u201352. https:\/\/doi.org\/10.1016\/j.jacep.2015.09.001.","journal-title":"JACC: Clin Electrophysiol"},{"key":"2347_CR9","doi-asserted-by":"publisher","unstructured":"Anter E, Kleber AG, Rottmann M, Leshem E, Barkagan M, Tschabrunn CM et al. Infarct-Related Ventricular Tachycardia: Redefining the Electrophysiological Substrate of the Isthmus During Sinus Rhythm. JACC: Clinical Electrophysiology. 2018. https:\/\/doi.org\/10.1016\/j.jacep.2018.04.007","DOI":"10.1016\/j.jacep.2018.04.007"},{"issue":"1","key":"2347_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/europace\/euac140","volume":"25","author":"E Sung","year":"2023","unstructured":"Sung E, Prakosa A, Kyranakis S, Berger RD, Chrispin J, Trayanova NA. Wavefront directionality and decremental stimuli synergistically improve identification of ventricular tachycardia substrate: insights from personalized computational heart models. Europace. 2023;25(1):223\u201335. https:\/\/doi.org\/10.1093\/europace\/euac140.","journal-title":"Europace"},{"issue":"8","key":"2347_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa2409501","volume":"392","author":"JL Sapp","year":"2025","unstructured":"Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Gula LJ, et al. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. 2025;392(8):737\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2409501.","journal-title":"N Engl J Med"},{"issue":"25","key":"2347_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.122.060039","volume":"145","author":"R Tung","year":"2022","unstructured":"Tung R, Xue Y, Chen M, Jiang C, Shatz DY, Besser SA, et al. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation. 2022;145(25):1839\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060039.","journal-title":"Circulation"},{"key":"2347_CR13","doi-asserted-by":"publisher","unstructured":"Eckardt L, Doldi F, Anwar O, Gessler N, Scherschel K, Kahle AK, et al. Major in-hospital complications after catheter ablation of cardiac arrhythmias: individual case analysis of 43 031 procedures. Europace. 2023;26(1). https:\/\/doi.org\/10.1093\/europace\/euad361.","DOI":"10.1093\/europace\/euad361"},{"issue":"13","key":"2347_CR14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jacep.2017.07.005","volume":"3","author":"MK Turagam","year":"2017","unstructured":"Turagam MK, Vuddanda V, Atkins D, Santangeli P, Frankel DS, Tung R, et al. Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study. JACC: Clin Electrophysiol. 2017;3(13):1534\u201343. https:\/\/doi.org\/10.1016\/j.jacep.2017.07.005.","journal-title":"JACC: Clin Electrophysiol"},{"issue":"5","key":"2347_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jacc.2023.05.012","volume":"82","author":"J Sroubek","year":"2023","unstructured":"Sroubek J, Vajapey R, Sipko JJ, Soltesz EG, Weiss AJ, Bhargava M, et al. First-in-Human Experience With Impella 5.0\/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation. J Am Coll Cardiol. 2023;82(5):469\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.012.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2347_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.hrthm.2011.03.008","volume":"8","author":"HM Haqqani","year":"2011","unstructured":"Haqqani HM, Tschabrunn CM, Tzou WS, Dixit S, Cooper JM, Riley MP, et al. Isolated septal substrate for ventricular tachycardia in nonischemic dilated cardiomyopathy: incidence, characterization, and implications. Heart Rhythm. 2011;8(8):1169\u201376. https:\/\/doi.org\/10.1016\/j.hrthm.2011.03.008.","journal-title":"Heart Rhythm"},{"issue":"9","key":"2347_CR17","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.jacep.2023.05.028","volume":"9","author":"MR Arceluz","year":"2023","unstructured":"Arceluz MR, Thind M, Hambach B, Garcia FC, Callans DJ, Guandalini GS, et al. Septal Substrate Ablation Guided by Delayed Transmural Conduction Times: A Novel Ablation Approach to Target Intramural Substrates. JACC Clin Electrophysiol. 2023;9(9):1903\u201313. https:\/\/doi.org\/10.1016\/j.jacep.2023.05.028.","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-026-02347-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:04:41Z","timestamp":1793916281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-026-02347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1007\/s10840-026-02347-1","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Cleveland Clinic Institutional Review Board. All study subjects provided written informed consent.","order":1,"name":"Ethics","label":"Ethics Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NCT04477499 (clinicaltrials.gov database).","order":2,"name":"Ethics","label":"Trial Registration Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Sroubek has received speaking fees from Biosense Webster and Abbott and receives research grant support from Abbott. Dr. Higuchi has served as a consultant for Abbott. Dr. Hussein receives research grant support from Boston Scientific. Dr. Varma has served as a consultant for Abbott, Biotronik, Boston Scientific and Medtronic. Dr. Wazni has served as a consultant for Abbott, Biosense Webster, Boston Scientific and Medtronic. Dr. Anter is a consultant to and has received equity from Affera-Medtronic. He serves in consulting and advisory capacities for Biosense Webster, Boston Scientific, and Abbott Medical. He receives research grants from Biosense Webster and Medtronic. Dr. Bhargava has reported that he has no relationships relevant to the contents of this paper to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}